2019 Hedge Fund

6 Acquisition International - Hedge Fund Awards 2019 Dec18452 Boxer Capital, LLC invents and invests in biotechnology companies that aim to drastically improve medicine. To celebrate the firm’s success in this year’s Hedge Fund Awards we profile it to find out more and explore the secrets behind its success. stablished in 2005 by Co-Founder, CEO, and Portfolio Manager, Aaron Davis; Co-Founder, Chris Fuglesang and its investor, Joe Lewis of the Tavistock Group, Boxer Capital leverages its internal expertise within the drug development and biotechnology industry to evaluate pre-clinical and clinical data from biotechnology companies that are positioned to generate outsized returns. Boxer Capital, LLC Boxer Capital maintains a portfolio of public and private companies, with a focus on biotechnology drug development across multiple therapeutic indications. Since its inception in 2005, the firm has achieved remarkable success, generating a 34% IRR and a cumulative return of 4,546%. In 2018, the firm generated an annual return of 70%, which, as notable as this is, still only serves as its fourth best annual return to date. Eight of the past 13 years, the firm has generated 30%+ returns. Beyond its monetary growth, Boxer Capital has supported the advancement of therapeutic breakthroughs for oncology and rare disease patients through its wide-ranging investments in companies including: • AveXis Inc. (AVXS): AVXS developed the proprietary gene therapy, AVXS-101, that changed disease progression of Spinal Muscular Atrophy (“SMA”) and ultimately led to the company’s acquisition by Novartis in April of 2018 for $8.7 billion USD • BeiGene Ltd. (BGNE): BGNE takes an innovative approach in developing molecularly targeted and immune-oncology drugs to treat cancer • Blueprint Medicines Corporation (BPMC): BPMC’s platform seeks to deliver a new generation of highly selective kinase therapies to dramatically improve patients’ lives • Cougar Biotechnology (acquired by J&J in 2009): Cougar focused on treating metastatic castration-resistant prostate cancer through Company: Boxer Capital, LLC Contact: Aaron Davis Website: www.boxercap.com E Through their work at Boxer Capital, this dynamic team researches potential avenues for innovative breakthroughs in science that they can advance through financing and support. Their impressive success rate has led to remarkable progress not only in creating outsized returns, but also in bringing medical dreams to reality. This focused investment approach holds promise to drive innovative discoveries that represent potential to transform health outcomes for patients.